ATE176868T1 - Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper - Google Patents

Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper

Info

Publication number
ATE176868T1
ATE176868T1 AT92915866T AT92915866T ATE176868T1 AT E176868 T1 ATE176868 T1 AT E176868T1 AT 92915866 T AT92915866 T AT 92915866T AT 92915866 T AT92915866 T AT 92915866T AT E176868 T1 ATE176868 T1 AT E176868T1
Authority
AT
Austria
Prior art keywords
igg antibodies
monoclonal human
stabilized preparation
state
monoclonal antibody
Prior art date
Application number
AT92915866T
Other languages
English (en)
Inventor
Hideaki Hagiwara
Hideo Yuasa
Yasunori Yamamoto
Original Assignee
Hagiwara Yoshihide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16495593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE176868(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hagiwara Yoshihide filed Critical Hagiwara Yoshihide
Application granted granted Critical
Publication of ATE176868T1 publication Critical patent/ATE176868T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT92915866T 1991-07-20 1992-07-17 Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper ATE176868T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3204743A JP2966592B2 (ja) 1991-07-20 1991-07-20 安定化されたヒトモノクローナル抗体製剤

Publications (1)

Publication Number Publication Date
ATE176868T1 true ATE176868T1 (de) 1999-03-15

Family

ID=16495593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92915866T ATE176868T1 (de) 1991-07-20 1992-07-17 Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper

Country Status (6)

Country Link
EP (1) EP0597101B1 (de)
JP (1) JP2966592B2 (de)
AT (1) ATE176868T1 (de)
AU (1) AU662010B2 (de)
DE (1) DE69228474T2 (de)
WO (1) WO1993001835A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814841B1 (de) * 1995-03-21 2001-12-05 Applied Research Systems ARS Holding N.V. Flüssige hcg-formulierungen
CN1082368C (zh) * 1995-03-21 2002-04-10 应用研究系统Ars股份公司 人绒毛膜促性腺激素液体制剂
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CA2278546C (en) * 1997-01-30 2008-04-01 Hoechst Marion Roussel Ltd. Freeze-dried composition of bone morphogenetic protein human mp52
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP3578168A1 (de) * 2002-02-14 2019-12-11 Chugai Seiyaku Kabushiki Kaisha Formulierung von antikörperhaltigen lösungen mit einem zucker als stabilisator
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
FR2853551B1 (fr) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
ES2562912T5 (es) 2003-10-01 2020-02-18 Kyowa Hakko Kirin Co Ltd Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2868401C (en) * 2012-03-26 2021-08-24 Sanofi Stable anti-cxcr5 igg4 antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5347515A (en) * 1976-10-13 1978-04-28 Green Cross Corp:The Gamma-globulin pharmaceutical preparation for intravenous injection
JPS56127320A (en) * 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Gamma-globulin pharmaceutical
US4808621A (en) * 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
EP0410207B1 (de) * 1989-07-24 1997-01-22 Bayer Corporation Stabilisierung von hochgereinigten Proteinen

Also Published As

Publication number Publication date
JP2966592B2 (ja) 1999-10-25
DE69228474D1 (de) 1999-04-01
WO1993001835A1 (en) 1993-02-04
DE69228474T2 (de) 1999-06-24
AU2330592A (en) 1993-02-23
JPH0525058A (ja) 1993-02-02
EP0597101A1 (de) 1994-05-18
EP0597101B1 (de) 1999-02-24
EP0597101A4 (en) 1994-06-15
AU662010B2 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
ATE176868T1 (de) Stabilisierte aufbereitung monoklonaler menschlicher cln-igg antikörper
Finkelstein et al. Pathogenesis of experimental cholera: biologic activities of purified procholeragen A
ATE122357T1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
IE823046L (en) Stabilised interferon formulations
ZA876807B (en) Monoclonal antibodies against human tumor necrosis factor(tnf),and use thereof
OA08749A (fr) Vaccins dont l'épitope caractéristique est incorporé dans une protéine de picornavirus, notamment de poliovirus.
DE3685651T2 (de) Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
IL132414A0 (en) Type alpha platelet derived growth factor receptor gene
ATE174794T1 (de) Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien
ATE174625T1 (de) Rekombinante hybride porinepitope
ATE164311T1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
ES2060695T3 (es) Concentrados terapeuticos de igm.
AU5435990A (en) Monoclonal antibodies to human glutathione s transferase pi
CA2106563A1 (en) Cocaine derivatives and protein and polypeptide cocaine derivative conjugates and labels
KR900700079A (ko) 누출방지 리포좀 제제
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
MA21448A1 (fr) Procede de preparation de structures peptidiques et immunogenes les contenant destines au controle de la fertilite.
WO1989000166A3 (en) Growth hormone related peptide
EP0254845A3 (de) Immun-Stimulation mit Chondroitin-sulfat
EP0213595A3 (de) Transferrine und ihre Verwendung
ATE175357T1 (de) Empfängnisverhütender impfstoff
RU95104722A (ru) Способ получения антител к коринебактериям дифтерии
Mazzola In antibodies, bigger isn't always better
Nizamov et al. Carbonic anhydrase: A marker of cell types in guinea pig vas deferens cell culture
KR880001806A (ko) γ-인터페론의 제조방법과 그 용도

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee